. 2021 Jan 27;12(6):962–969. doi: 10.1111/1759-7714.13817

Table 3.

Summary of osimertinib acquired resistant NSCLC patients induced by ALK rearrangement

				First‐line treatment		Second‐line treatment		Third‐line treatment		Ongoing treatment
Contributors	Case	Gender	Age	Molecular detection; treatment	PFS (months)	Molecular detection; treatment	PFS (months)	Molecular detection; treatment	PFS (months)	Molecular detection; treatment	PFS (months)
Zhang, et al. ¹³	^#1	Male	66	EGFR 19 del; gefitinib	18	EGFR T790M (+); osimertinib	14	EGFR 19del, T790M(+), C797G in cis(+), EML4‐ALK; crizotinib	1	No molecular detection; pemetrexed + bevacizumab	NA ^#
Zhou, et al. ¹⁴	^#2	Male	42	EGFR 19 del; gefitinib	10	EGFR T790M (+); osimertinib	5	EGFR19del, T790M(−), STRN‐ALK; gefitinib+crizotinib	6	—	—
Hou, et al	^#3	Female	60	EGFR 19 del; gefitinib	18.3	EGFR T790M (−); osimertinib	11.6	EGFR 19del, T790M (−), CDK4 Amp, EML4‐ALK; osimertinib + crizotinib	6	EML4‐ALK, EGFR 19del, VEGFA Amp; osimertinib^* + chemotherapy + bevacizumab	Over 17 months
Schrock et al. ¹⁵	^#4	Female	70	EGFR L858R; erlotinib	12	EGFR T790M (+); afatinib	2	EGFR T790M (+); osimertinib	10	EGFR L858R, EGFR T790M (+), PLEKHA7‐ALK; osimertinib + alectinib	6
Offin et al. ¹⁶	#5	Female	65	EGFR 19 del; erlotinib	19	EGFR T790M (+); osimertinib + necitumumab	9	EGFR 19del, T790M(+), EML4‐ALK; osimertinib + crizotinib	NA ^#	—	—
Offin et al. ¹⁶	#6	Female	68	EGFR L858R; erlotinib	15	EGFR T790M (+); osimertinib	6	EGFR L858R, T790M (+), EML4‐ALK; alectinib	NA ^#	—	—
Liang et al. ¹⁷	#7	Female	46	EGFR 19 del; erlotinib	4	No molecular detection; pemetrexed + bevacizumab	0	No molecular detection; osimertinib (followed 2‐cycle GP regimen chemotherapy)	2	EGFR 19 del, EGFR L747S, EML4‐ALK; osimertinib + crizotinib/brigatinib^*	NA ^#

Case 3: Osimertinib was discontinued as a result of its cardiac toxicity as shown in Table 2.

Case 7 was evaluated as progressive disease after two months of osimertinib plus crizotinib treatment and the regimen was changed to osimertinib plus brigatinib.

^{^#}

NA, not available. Patients maintained a continuous stable disease.